As on Wednesday, Autolus Therapeutics plc ADR (NASDAQ: AUTL) started slowly as it slid -6.03% to $4.21, before settling in for the price of $4.48 at the close. Taking a more long-term approach, AUTL posted a 52-week range of $1.61-$7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 152.23%. Meanwhile, its Annual Earning per share during the time was 3.32%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 42.57%. This publicly-traded company’s shares outstanding now amounts to $174.10 million, simultaneously with a float of $157.78 million. The organization now has a market capitalization sitting at $732.96 million. At the time of writing, stock’s 50-day Moving Average stood at $5.75, while the 200-day Moving Average is $4.40.
Autolus Therapeutics plc ADR (AUTL) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Autolus Therapeutics plc ADR’s current insider ownership accounts for 9.38%, in contrast to 61.00% institutional ownership.
Autolus Therapeutics plc ADR (AUTL) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 12/31/2023, the company posted -0.23 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.27) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
Autolus Therapeutics plc ADR’s EPS increase for this current 12-month fiscal period is 42.57% and is forecasted to reach -0.57 in the upcoming year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Let’s observe the current performance indicators for Autolus Therapeutics plc ADR (AUTL). It’s Quick Ratio in the last reported quarter now stands at 6.11. The Stock has managed to achieve an average true range (ATR) of 0.34. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 431.15.
In the same vein, AUTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.20, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.57 at the market close of one year from today.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Through scrutinizing the latest numbers posted by the [Autolus Therapeutics plc ADR, AUTL], it can be observed that its last 5-days Average volume of 1.64 million was better the volume of 1.52 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 4.78% While, its Average True Range was 0.33.
Raw Stochastic average of Autolus Therapeutics plc ADR (AUTL) in the period of the previous 100 days is set at 11.23%, which indicates a major rise in contrast to 3.87% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 45.29% that was lower than 67.92% volatility it exhibited in the past 100-days period.
